JP6989489B2 - Nsaidのための固溶体組成物 - Google Patents
Nsaidのための固溶体組成物 Download PDFInfo
- Publication number
- JP6989489B2 JP6989489B2 JP2018506262A JP2018506262A JP6989489B2 JP 6989489 B2 JP6989489 B2 JP 6989489B2 JP 2018506262 A JP2018506262 A JP 2018506262A JP 2018506262 A JP2018506262 A JP 2018506262A JP 6989489 B2 JP6989489 B2 JP 6989489B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- solid solution
- room temperature
- pharmaceutical composition
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明の1つの目的は、NSAIDを含む改良された固溶体組成物を提供することにある。
i)25重量%〜31重量%の非ステロイド性抗炎症薬(NSAID)、
ii)34重量%〜40重量%の室温すなわち20℃で固体の脂質、
iii)22重量%〜28重量%の室温すなわち20℃で液体の脂質、および
iv)7重量%〜13重量%の液体グリコールポリマーを含む安定化剤
を含む医薬組成物が提供される。
a)25重量%〜31重量%のイブプロフェン、
b)34重量%〜40重量%の室温すなわち20℃で固体の混合物である飽和C10〜C18トリグリセリドの混合物、
c)22重量%〜28重量%の室温すなわち20℃で液体のモノグリセリド、
d)7重量%〜13重量%のポリオキシエチレンポリマーを含む安定化剤、および
e)0.5重量%以下の親水性溶媒
を含み、正常なヒトの体温すなわち37℃で液体であり、かつ室温すなわち20℃で固体である固溶体医薬組成物を提供する。
200gの量のイブプロフェン25(EP)を175.08gの室温で液体の脂質、すなわちモノリノール酸グリセリン(EP、NF)(MAISINE(商標)35−1として市販されている)に溶解した。72.3gの安定化剤マクロゴール400(EP)(PEG400(NF))を添加し、この混合物を50℃〜60℃の温度まで加熱した。
U937単球細胞株の培養液を細胞が90%コンフルエントな単層に達するまで10%ウシ胎児血清(FCS)を添加したRPMl−1640で増殖させた。次いで、細胞がマクロファージに分化するまでこれらの細胞をPMAで処理し、5%二酸化炭素中37℃のインキュベーターでインキュベートした。
1.イブプロフェン、GELUCIRE(登録商標)43/01(Gattefosse社)、MAISINE(商標)35−1(Gattefosse社)およびPEG400(すなわち充填物成分)を含む実施例1の固溶体製剤
2.イブプロフェン遊離酸
3.治療用化合物を含まない媒体
特許請求されている組成物中の各種成分の融点を示すために示差走査熱量測定(DSC)を使用した。その結果は図1に示されている。
ヒトにおいて特許請求されている組成物の安全性および有効性を試験するために、以下に記載するように臨床試験を開発した。
Claims (15)
- a)27重量%〜29重量%の非ステロイド性抗炎症薬(NSAID)、
b)34重量%〜40重量%の室温すなわち20℃で固体の飽和C10〜C18トリグリセリドの混合物、
c)22重量%〜28重量%の室温すなわち20℃で液体のモノグリセリドを含む1種以上の部分的に加水分解された脂肪、および
d)7重量%〜13重量%の液体グリコールポリマーを含む安定化剤
を含む固溶体医薬組成物であり、
前記固溶体医薬組成物は、正常なヒトの体温すなわち37℃で液体であり、かつ室温すなわち20℃で固体である、固溶体医薬組成物。 - 前記NSAIDはイブプロフェンである、請求項1に記載の固溶体医薬組成物。
- 36重量%〜38重量%の(b)を含む、請求項1または2に記載の固溶体医薬組成物。
- 23重量%〜25重量%の(c)を含む、請求項1〜3のいずれか一項に記載の固溶体医薬組成物。
- 9重量%〜11重量%の(d)を含む、請求項1〜4のいずれか一項に記載の固溶体医薬組成物。
- 前記飽和C10〜C18トリグリセリドは、41℃〜45℃の融点を有する、請求項1〜5のいずれか一項に記載の固溶体医薬組成物。
- (c)は、モノリノール酸グリセリンを含む、請求項1〜6のいずれか一項に記載の固溶体医薬組成物。
- (d)は液体ポリエチレングリコールポリマーまたは液体ポリプロピレングリコールポリマーを含む、請求項1〜7のいずれか一項に記載の固溶体医薬組成物。
- 前記ポリエチレングリコールポリマーは、PEG100、PEG200、PEG300、PEG400、PEG500、PEG600、PEG700、PEG800、PEG900、PEG1000またはそれらの任意の組み合わせを含む、請求項8に記載の固溶体医薬組成物。
- 室温で固体である前記飽和C 10 〜C 18 トリグリセリドの混合物はGELUCIRE(登録商標)43/01を含み、室温で液体である前記1種以上の部分的に加水分解された脂肪はMASINE(商標)35−1を含む、請求項1〜9のいずれか一項に記載の固溶体医薬組成物。
- a)27重量%〜29重量%のイブプロフェン、
b)34重量%〜40重量%の室温すなわち20℃で固体の飽和C10〜C18トリグリセリドの混合物、
c)22重量%〜28重量%の室温すなわち20℃で液体のモノグリセリドを含む1種以上の部分的に加水分解された脂肪、および
d)7重量%〜13重量%のポリオキシエチレンポリマーを含む安定化剤、
を含む固溶体医薬組成物であって、
前記固溶体医薬組成物は、正常なヒトの体温すなわち37℃で液体であり、かつ室温すなわち20℃で固体である、請求項1〜10のいずれか一項に記載の固溶体医薬組成物。 - 前記飽和C10〜C18トリグリセリドの混合物は、41℃〜45℃の融点を有する、請求項11に記載の固溶体医薬組成物。
- 前記飽和C10〜C18トリグリセリドの混合物はGELUCIRE(登録商標)43/01であり、前記1種以上の部分的に加水分解された脂肪はMAISINE(商標)35−1である、請求項11または12に記載の固溶体医薬組成物。
- 経口剤形である、請求項1〜13のいずれか一項に記載の固溶体医薬組成物。
- 炎症、疼痛または慢性炎症を治療するのに使用される、請求項1〜14のいずれか1項に記載の固溶体医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/821,687 US9744132B2 (en) | 2010-10-29 | 2015-08-07 | Solid solution compositions and use in chronic inflammation |
EP15180256.8A EP3127556A1 (en) | 2015-08-07 | 2015-08-07 | Solid solution compositions for nsaid |
US14/821,687 | 2015-08-07 | ||
EP15180256.8 | 2015-08-07 | ||
PCT/EP2016/068900 WO2017025517A1 (en) | 2015-08-07 | 2016-08-08 | SOLID SOLUTION COMPOSITIONS FOR NSAIDs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018526351A JP2018526351A (ja) | 2018-09-13 |
JP2018526351A5 JP2018526351A5 (ja) | 2019-09-12 |
JP6989489B2 true JP6989489B2 (ja) | 2022-01-05 |
Family
ID=56800263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018506262A Active JP6989489B2 (ja) | 2015-08-07 | 2016-08-08 | Nsaidのための固溶体組成物 |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP3988091A1 (ja) |
JP (1) | JP6989489B2 (ja) |
CN (1) | CN108025078A (ja) |
AU (1) | AU2016306610B2 (ja) |
CA (1) | CA2994899C (ja) |
ES (1) | ES2906571T3 (ja) |
IL (1) | IL257385A (ja) |
MX (1) | MX2018001584A (ja) |
PL (1) | PL3331568T3 (ja) |
WO (1) | WO2017025517A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US9308213B2 (en) * | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695432B2 (en) * | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
JP6389190B2 (ja) * | 2013-01-14 | 2018-09-12 | インファースト ヘルスケア リミテッド | 固溶体組成物および慢性炎症における使用 |
-
2016
- 2016-08-08 PL PL16756963T patent/PL3331568T3/pl unknown
- 2016-08-08 CA CA2994899A patent/CA2994899C/en active Active
- 2016-08-08 AU AU2016306610A patent/AU2016306610B2/en active Active
- 2016-08-08 EP EP21214529.6A patent/EP3988091A1/en active Pending
- 2016-08-08 EP EP16756963.1A patent/EP3331568B1/en active Active
- 2016-08-08 ES ES16756963T patent/ES2906571T3/es active Active
- 2016-08-08 JP JP2018506262A patent/JP6989489B2/ja active Active
- 2016-08-08 CN CN201680054597.5A patent/CN108025078A/zh active Pending
- 2016-08-08 MX MX2018001584A patent/MX2018001584A/es unknown
- 2016-08-08 WO PCT/EP2016/068900 patent/WO2017025517A1/en active Application Filing
-
2018
- 2018-02-07 IL IL257385A patent/IL257385A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL257385A (en) | 2018-04-30 |
WO2017025517A1 (en) | 2017-02-16 |
MX2018001584A (es) | 2019-01-31 |
PL3331568T3 (pl) | 2022-02-28 |
EP3988091A1 (en) | 2022-04-27 |
CA2994899C (en) | 2024-04-16 |
CA2994899A1 (en) | 2017-02-16 |
ES2906571T3 (es) | 2022-04-19 |
AU2016306610B2 (en) | 2019-02-28 |
AU2016306610A1 (en) | 2018-03-01 |
EP3331568B1 (en) | 2021-12-15 |
EP3331568A1 (en) | 2018-06-13 |
JP2018526351A (ja) | 2018-09-13 |
CN108025078A (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6989489B2 (ja) | Nsaidのための固溶体組成物 | |
US10653778B2 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
JP2021185179A (ja) | 固溶体組成物および心血管疾患における使用 | |
AU2014211715B2 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
CA2826452C (en) | Compositions and methods for treating cardiovascular diseases | |
JP6474732B2 (ja) | 激痛治療用組成物と方法 | |
SG189551A1 (en) | Inflammatory disease | |
WO2016071365A1 (en) | Topical pharmaceutical compositions of paclitaxel | |
JP2018505905A (ja) | 局所医薬製剤 | |
JP7515582B2 (ja) | シクロオキシゲナーゼ阻害剤の局所配合剤およびその使用 | |
EP3127556A1 (en) | Solid solution compositions for nsaid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201211 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210727 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210727 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210810 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211008 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6989489 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |